Satumomab, also known as B72.3, is a modified mouse monoclonal antibody which could specifically bind to tumor-associated glycoprotein (TAG-72). This antibody was developed by Cytogen Corporation, which was acquired by EUSA Pharma in 2008. Satumomab is usually combined with some radioactive elements to diagnose colorectal cancer and ovarian cancer.